Widespread renal polycystosis induced by crizotinib

Marco Di Girolamo, Ida Paris, Francesco Carbonetti, Elisa Concetta Onesti, Fabio Socciarelli, Paolo Marchetti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

With the widespread availability of biological antitumor drugs, the current scene of chemotherapies is changing. New chemotherapy agents, such as crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, usually used in pretreated advanced ALK-positive non-small-cell lung carcinoma, are more often used, and a description of the onset of side effects with suggestions for their management could be of interest for physicians. We describe a case of diffuse and aggressive renal polycystosis induced by crizotinib, which regressed after therapy, which could be of interest considering its wide extension and disappearance after the end of treatment. We also suggest some considerations from the literature and from the case reported that could be helpful in the management of this condition, which is known to be caused by crizotinib treatment.

Original languageEnglish
Pages (from-to)e128-e131
JournalTumori
Volume101
Issue number4
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Kidney
Drug Therapy
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Biological Availability
Therapeutics
Physicians
crizotinib
anaplastic lymphoma kinase

Keywords

  • Adverse reactions
  • Drug-related side effects
  • Kidney diseases
  • Lung neoplasms
  • Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Di Girolamo, M., Paris, I., Carbonetti, F., Onesti, E. C., Socciarelli, F., & Marchetti, P. (2015). Widespread renal polycystosis induced by crizotinib. Tumori, 101(4), e128-e131. https://doi.org/10.5301/tj.5000338

Widespread renal polycystosis induced by crizotinib. / Di Girolamo, Marco; Paris, Ida; Carbonetti, Francesco; Onesti, Elisa Concetta; Socciarelli, Fabio; Marchetti, Paolo.

In: Tumori, Vol. 101, No. 4, 01.07.2015, p. e128-e131.

Research output: Contribution to journalArticle

Di Girolamo, M, Paris, I, Carbonetti, F, Onesti, EC, Socciarelli, F & Marchetti, P 2015, 'Widespread renal polycystosis induced by crizotinib', Tumori, vol. 101, no. 4, pp. e128-e131. https://doi.org/10.5301/tj.5000338
Di Girolamo M, Paris I, Carbonetti F, Onesti EC, Socciarelli F, Marchetti P. Widespread renal polycystosis induced by crizotinib. Tumori. 2015 Jul 1;101(4):e128-e131. https://doi.org/10.5301/tj.5000338
Di Girolamo, Marco ; Paris, Ida ; Carbonetti, Francesco ; Onesti, Elisa Concetta ; Socciarelli, Fabio ; Marchetti, Paolo. / Widespread renal polycystosis induced by crizotinib. In: Tumori. 2015 ; Vol. 101, No. 4. pp. e128-e131.
@article{93be8ced71e24d04886443efa1c6dcc8,
title = "Widespread renal polycystosis induced by crizotinib",
abstract = "With the widespread availability of biological antitumor drugs, the current scene of chemotherapies is changing. New chemotherapy agents, such as crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, usually used in pretreated advanced ALK-positive non-small-cell lung carcinoma, are more often used, and a description of the onset of side effects with suggestions for their management could be of interest for physicians. We describe a case of diffuse and aggressive renal polycystosis induced by crizotinib, which regressed after therapy, which could be of interest considering its wide extension and disappearance after the end of treatment. We also suggest some considerations from the literature and from the case reported that could be helpful in the management of this condition, which is known to be caused by crizotinib treatment.",
keywords = "Adverse reactions, Drug-related side effects, Kidney diseases, Lung neoplasms, Therapeutics",
author = "{Di Girolamo}, Marco and Ida Paris and Francesco Carbonetti and Onesti, {Elisa Concetta} and Fabio Socciarelli and Paolo Marchetti",
year = "2015",
month = "7",
day = "1",
doi = "10.5301/tj.5000338",
language = "English",
volume = "101",
pages = "e128--e131",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Widespread renal polycystosis induced by crizotinib

AU - Di Girolamo, Marco

AU - Paris, Ida

AU - Carbonetti, Francesco

AU - Onesti, Elisa Concetta

AU - Socciarelli, Fabio

AU - Marchetti, Paolo

PY - 2015/7/1

Y1 - 2015/7/1

N2 - With the widespread availability of biological antitumor drugs, the current scene of chemotherapies is changing. New chemotherapy agents, such as crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, usually used in pretreated advanced ALK-positive non-small-cell lung carcinoma, are more often used, and a description of the onset of side effects with suggestions for their management could be of interest for physicians. We describe a case of diffuse and aggressive renal polycystosis induced by crizotinib, which regressed after therapy, which could be of interest considering its wide extension and disappearance after the end of treatment. We also suggest some considerations from the literature and from the case reported that could be helpful in the management of this condition, which is known to be caused by crizotinib treatment.

AB - With the widespread availability of biological antitumor drugs, the current scene of chemotherapies is changing. New chemotherapy agents, such as crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, usually used in pretreated advanced ALK-positive non-small-cell lung carcinoma, are more often used, and a description of the onset of side effects with suggestions for their management could be of interest for physicians. We describe a case of diffuse and aggressive renal polycystosis induced by crizotinib, which regressed after therapy, which could be of interest considering its wide extension and disappearance after the end of treatment. We also suggest some considerations from the literature and from the case reported that could be helpful in the management of this condition, which is known to be caused by crizotinib treatment.

KW - Adverse reactions

KW - Drug-related side effects

KW - Kidney diseases

KW - Lung neoplasms

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84942872538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942872538&partnerID=8YFLogxK

U2 - 10.5301/tj.5000338

DO - 10.5301/tj.5000338

M3 - Article

VL - 101

SP - e128-e131

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -